Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Two-Arm, Open-Label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif New Formulation From Rebif (Interferon Beta-1a) [subcutaneously injected, 44mcg three-times-weekly] With Ibuprofen PRN [when necessary] or as Prophylaxis

Next Previous
X
Search
Trial Profile

Randomized, Multicenter, Two-Arm, Open-Label, Phase IIIb Study to Evaluate the Satisfaction in Relapsing Multiple Sclerosis Subjects Transitioning to Rebif New Formulation From Rebif (Interferon Beta-1a) [subcutaneously injected, 44mcg three-times-weekly] With Ibuprofen PRN [when necessary] or as Prophylaxis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary) ; Ibuprofen
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRANSFER; Transition to RNF
  • Sponsors EMD Serono; Merck KGaA; Merck Serono

    • Most Recent Events

    • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
    • 13 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Sep 2008 Primary endpoint results presented at ECTRIMS/ACTRIMS/LACTRIMS

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top